Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis, Anadys end toll-like receptor deal

Executive Summary

Just one day after signing an agreement with Hybridon, Novartis has signed another toll-like receptor (TLR) deal, this time with Anadys Pharmaceuticals (developing therapeutics for infectious and viral diseases). Novartis gets the exclusive worldwide development, manufacturing, and marketing rights to Anadys's ANA975 and other toll-like receptor 7 oral prodrugs for chronic hepatitis B and C viruses and other infectious diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register